<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01731067</url>
  </required_header>
  <id_info>
    <org_study_id>Coktail DBS</org_study_id>
    <nct_id>NCT01731067</nct_id>
  </id_info>
  <brief_title>Cocktail Approach for Cytochrome P450 and P-glycoprotein Activity Assessment Using Dried Blood Spot</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Desmeules</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Geneva</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phenotyping is an approach largely used for the evaluation of the activity of cytochromes and
      transporters in vivo. It consists of the administration of probe substances metabolised by a
      specific cytochrome or transported by P-glycoprotein (P-gp) for example, followed by the
      determination of a metabolic ratio or the evaluation of the plasmatic or urinary
      concentrations of the probe substances. The administration of a cocktail containing several
      probe substances allows the simultaneous evaluation of the activity of several cytochromes
      and P-gp in a single test.

      The aim of this project is the validation of a phenotyping cocktail of low dose probe drugs
      for the assessment of cytochrome P450 and P-gp activities by simple capillary blood sampling
      and dried blood spot (DBS) analysis. The cocktail consists of caffeine, bupropion,
      flurbiprofen, omeprazole, dextromethorphan, midazolam and fexofenadine for the simultaneous
      phenotyping of CYP1A2, CYP2B6, CYP2C9, CAP2C19, CYP2D6, CYP3A4 and P-gp, respectively.

      The modulation of the activity of cytochromes or P-gp will be evaluated by the administration
      of inhibitors (fluvoxamine, voriconazole, quinidine) or inducer (rifampicin) of the metabolic
      pathways or the P-gp mediated transport.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Probe cocktail drugs plasma and capillary concentrations in presence/absence of CYP1A2,2B6, 2C9, 2C19, 2D6, 3A4 and P-gp inhibitor or inducer</measure>
    <time_frame>4 singles days spaced out with one week wash-out periods</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>correlation between plasma or urine and capillary concentrations for each probe cocktail drug</measure>
    <time_frame>4 singles days spaced out with one week wash-out periods</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>comparison. between genotype and phenotype for each enzyme</measure>
    <time_frame>one day</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral intake of fluvoxamine (50 mg per day during 2 days) and voriconazole (400 mg) before oral intake of the cocktail probe drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYP2D6 and P-gp inhibitor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral intake of quinidine (200 mg) before oral intake of the cocktail probe drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CYPs and P-gp inducer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral intake of rifampicin (600 mg per day during 7 days) before oral intake of the cocktail probe drugs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Probe cocktail alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral intake of the cocktail probe drugs :
bupropion 25 mg
flurbiprofen 25 mg
omeprazole 5 mg
dextromethorphan 5 mg
midazolam 1 mg
fexofenadine 25mg
Caffeine (a cup of coffee)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cocktail probe drugs</intervention_name>
    <arm_group_label>CYP1A2, 2B6, 2C9, 2C19, 3A4 inhibitors</arm_group_label>
    <arm_group_label>CYP2D6 and P-gp inhibitor</arm_group_label>
    <arm_group_label>CYPs and P-gp inducer</arm_group_label>
    <arm_group_label>Probe cocktail alone</arm_group_label>
    <other_name>Oral intake of the cocktail probe drugs :</other_name>
    <other_name>bupropion 25 mg</other_name>
    <other_name>flurbiprofen 25 mg</other_name>
    <other_name>omeprazole 5 mg</other_name>
    <other_name>dextromethorphan 5 mg</other_name>
    <other_name>midazolam 1 mg</other_name>
    <other_name>fexofenadine 25mg</other_name>
    <other_name>Caffeine (a cup of coffee)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male volunteers aged from 18 to 60 years

          -  BMI between 18 and 25

          -  Understanding of French language and able to give a written inform consent.

        Exclusion Criteria:

          -  Smoker

          -  Taking drugs which alter CYPs activity

          -  Renal or hepatic impairment

          -  Medical history of porphyria

          -  Medical history of chronic alcoholism or abuse of psychoactive drugs

          -  Liver transplantation

          -  Sensitivity to any of the drugs used

          -  Wearing contact lenses (risk of coloration with rifampicin)

          -  ECG showing long QT interval (&gt;0.46sec)

          -  Alteration of hepatic tests

          -  Presenting genetic polymorphism of poor CYP 2B6, 2C9, 2C19, 2D6 metabolisers
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jules A Desmeules, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Geneva</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospitals</name>
      <address>
        <city>Geneva 14</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2012</study_first_submitted>
  <study_first_submitted_qc>November 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 21, 2012</study_first_posted>
  <last_update_submitted>September 15, 2014</last_update_submitted>
  <last_update_submitted_qc>September 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital, Geneva</investigator_affiliation>
    <investigator_full_name>Jules Desmeules</investigator_full_name>
    <investigator_title>Pr</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Caffeine</mesh_term>
    <mesh_term>Bupropion</mesh_term>
    <mesh_term>Dextromethorphan</mesh_term>
    <mesh_term>Fexofenadine</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Flurbiprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

